Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone

Xenobiotica

Volumn 34, Issue 11-12, 2004, Pages 1013-1023

  Simard, C ^a,b   Michaude, V ^b   Gibbs, B ^c   Masse R ^c   Lessardu, E ^d   Turgeon, J ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MDS Inc   (Canada)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CHLORZOXAZONE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEXTROMETHORPHAN; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DRUG METABOLITE; FURAFYLLINE; GLUCOSE 6 PHOSPHATE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; KETOCONAZOLE; MAGNESIUM CHLORIDE; MEPHENYTOIN; MONOCLONAL ANTIBODY; PROPANOL; QUINIDINE; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFAPHENAZOLE; TESTOSTERONE; TOLBUTAMIDE;

ARTICLE; CATALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; KINETICS; LIVER MICROSOME; LYMPHOBLASTOID CELL; METABOLITE;

EID: 11244267290     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250400015301     Document Type: Article

References (17)

1. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261-270.
2. BARONE, J. A., 1999, Domperidone: a peripherally acting dopamine2-receptor antagonist. Annals of Pharmacotherapy, 33, 429-440.
3. BROGDEN, R. N., CARMINE, A. A., HEEL, R. C., SPEIGHT, T. M. and AVERY, G. S., 1982, Domperidone, A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs, 24, 360-400.
4. CAMERON, H. A., REYNTJENS, A. J. and LAKE-BAKAAR, G., 1985, Cardiac arrest after treatment with intravenous domperidone. British Medical Journal, 290, 160.
5. CHOU, F., TZENG, S. and HUANG, J., 2001, Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metabolism and Disposition, 29, 1205-1209.
6. CLARKE, S. E., 1998, In vitro assessment of human cytochrome P450. Xenobiotica, 28, 1167-1202.
7. DROLET, B., ROUSSEAU, G., DALEAU, P., CARDINAL, R. and TURGEON, J., 2000, Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation, 102, 1883-1885.
8. HEYKANTS, J., HENDRICKX, R., MEULDERMANS, W., MICHIELS, M., SCHEYGROND, H. and REYNTJENS, H., 1981, On the pharmacokinetics of domperidone in animals and man IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. European Journal of Drug Metabolism and Pharmacokinetics, 6, 61-70.
9. KUEHL, P., ZHANG, J., LIN, Y., LAMBA, J., ASSEM, M., SCHUETZ, J., WATKINS, P. B., DALY, A., WRIGHTON, S. A., HALL, S. D., MAUREL, P., RELLING, M., BRIMER, C., YASUDA, K., VENKATARAMANAN, R., STROM, S., THUMMEL, K., BOGUSKI, M. and SCHUETZ, E., 2001, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics, 27, 383-391.
10. LESSARD, E., HAMELIN, B. A., LABBE, L., O'HARA, G. E., BÉLANGER, P. and TURGEON, J., 1999, Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. Pharmacogenetics, 9, 683-696.
11. MEULDERMANS, W., HURKMANS, R., SWYSEN, E., HENDRICKX, J., MICHIELS, M., LAUWERS, W. and HEYKANTS, J., 1981, On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. European Journal of Drug Metabolism and Pharmacokinetics, 6, 49-60.
12. NEWTON, D., WANG, R. and LU, A. H. Y., 1995. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
13. OSBORNE, R. J., SLEVIN, M. L., HUNTER, R. W. and HAMER, J., 1985a, Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone. Human Toxicology, 4, 617-626.
14. OSBORNE, R. J., SLEVIN, M. L., HUNTER, R. W. and HAMER, J., 1985b, Cardiotoxicity of intravenous domperidone. Lancet, ii, 385.
15. PRAKASH, A. and WAGSTAFF, A. J., 1998, Domperidone: A review of its use in diabetic gastropathy. Drugs, 56, 429-445.
16. QUINN, N., PARKES, D., JACKSON, G. and UPWARD, J., 1985, Cardiotoxicity of domperidone. Lancet, 28, 724.
17. ROUSSAK, J. B., CAREY, P. and PARRY, H., 1984, Cardiac arrest after treatment with intravenous domperidone. British Medical Journal, 289, 1579.